Evidence map›Paper›PMID 35369607›Full record

ArticleJTO clinical and research reports2022

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With

Makoto Nishio, Kazuto Nishio, Martin Reck, Edward B Garon, Fumio Imamura, Tomoya Kawaguchi, Hiroyuki Yamaguchi, Satoshi Ikeda, Katsuya Hirano, Carla Visseren-Grul and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Acquired Resistance to Osimertinib inInternational journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 5 countries.

Makoto NishioDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazuto NishioDepartment of Genome Biology, Kindai University, Faculty of Medicine, Osaka, Japan.
Martin ReckLungClinic, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.
Edward B GaronDepartment of Medicine, David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, California.
Fumio ImamuraDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Tomoya KawaguchiDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Hiroyuki YamaguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Satoshi IkedaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Katsuya HiranoDepartment of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Carla Visseren-GrulEli Lilly Netherlands, Utrecht, The Netherlands.
Matteo CeccarelliEli Lilly Italy, Sesto Fiorentino, Italy.
Sameera R WijayawardanaEli Lilly and Company, Indianapolis, Indiana.
Annamaria ZimmermannEli Lilly and Company, Indianapolis, Indiana.
Tomoko MatsuiEli Lilly Japan K.K., Kobe, Japan.
Sotaro EnatsuEli Lilly Japan K.K., Kobe, Japan.
Kazuhiko NakagawaDepartment of Medical Oncology, Kindai University, Faculty of Medicine, Osaka, Japan.
Eli Lilly (Japan) · JPEli Lilly (United States) · USKindai University · JPEli Lilly (Italy) · ITEli Lilly (Netherlands) · NLGerman Center for Lung Research · DEHyogo Prefectural Amagasaki General Medical Center · JPJapanese Foundation For Cancer Research · JPKanagawa Cardiovascular and Respiratory Center · JPNagasaki University · JPOsaka City University · JPOsaka International Cancer Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated Methods: Period 1 evaluated RAM (10 mg/kg) plus GEF (250 mg/d) in patients with untreated Results: From December 2017 to August 2018, a total of 82 patients were enrolled and started treatment (period 1, RAM + GEF). The 1-year PFS rate was 62.9% (95% confidence interval: 50.3-73.1). Treatment-emergent adverse events of grade three or higher were reported with RAM plus GEF in 60 of 82 patients (73.2%; five patients [6.1%] grade four). There were two deaths owing to adverse events that occurred (acute cardiac failure, congestive cardiac failure). T790M rate at disease progression in plasma was 81.0% (13 of 16 patients). Conclusions: RELAY+ was found to have a favorable benefit-risk profile for RAM plus GEF in first-line treatment of East Asian patients with

Indexed as

East AsiaJapanPlasma biopsyTreatment outcomeVascular endothelial growth factor receptor-2

Identifiers

PMID35369607
PMCPMC8966141
OpenAlexW4214751312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.